The Charles Schwab Corp. is looking for ways to boost the number of female financial advisers among its ranks after a survey found that 40% of its firms don’t have a single woman advising clients.
The solution is not something quick, easy or particularly well-demonstrated by other financial firms. It’s also something that Schwab’s female financial advisers likely will have to lead.
Schwab has formed a task force to tackle the issue, but several female advisers attending the Schwab Impact Conference in Washington D.C. this week said the first step should be to get their male counterparts to recognize that they should have a woman on their team — and that they should make an effort to find one.
Top 5 High Tech Companies To Watch For 2014: Dynavax Technologies Corporation(DVAX)
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The company’s lead product candidate includes HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide protection with fewer doses than current licensed vaccines. It also develops Universal Flu vaccine, a Phase 1b clinical trial vaccine for influenza prevention; SD-101, a Phase Ib clinical trial hepatitis C therapy; DV-601, a Phase Ib clinical trial hepatitis B therapy; AZD1419, a preclinical asthma therapy; and DV1179, a Phase 1 trial autoimmune and inflammatory disease therapy. Dynavax Technologies Corporation has strategic alliance with GlaxoSmithKline plc to discover, develop, and commercialize DV1179 and other endosomal toll-like receptor inhibitors for diseases, such as lupus, psoriasis, and rheumatoid arthritis; and develop a TLR8 inhibitor for the treatment of multiple autoimmune and i nflammatory diseases, as well as has research and license agreement with AstraZeneca to discover and develop TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was founded in 1996 and is based in Berkeley, California.
- [By Roberto Pedone]
Another under-$10 bio therapeutic player that’s starting to trend within range of triggering a major breakout trade is Dynavax Technologies (DVAX), which discovers and develops novel products to prevent and treat infectious and inflammatory diseases. This stock has been hit hard by the sellers so far in 2013, with shares off sharply by 55%.
If you take a look at the chart for Dynavax Technologies, you’ll notice that this stock has been trending inside of a big range for the last three months and change, with shares moving between $1.10 on the downside and $1.46 on the upside. This large consolidation pattern for DVAX could mean that this stock is under accumulation by the bulls, since the bears have been unable to push the stock out of this range and take it to new lows. Shares of DVAX are now starting to spike back above its 50-day moving average of $1.25 a share with decent upside volume. Volume so far on Thursday has already registered 1.6 million shares versus its three-month average action or 1.81 million shares. This move is starting to push DVAX within range of triggering a major breakout trade.
Market players should now look for long-biased trades in DVAX if it manages to break out above some key overhead resistance levels at $1.29 to $1.32 a share, and then once it takes out more resistance at $1.46 to $1.50 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 1.81 million shares. If that breakout hits soon, then DVAX will set up to re-test or possibly take out its next major overhead resistance level at $1.70 a share. Any high-volume move above $1.70 a share will then give DVAX a chance to re-fill some of its previous gap down zone from June that started at $2.60 a share.
Traders can look to buy DVAX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.10 a sha
- [By Rich Smith]
Berkeley, Calif.-based Dynavax Technologies (NASDAQ: DVAX ) has a new chief executive officer.
On Tuesday, the vaccine manufacturer announced that current CEO Dr. Dino Dina will retire on May 1, and will be succeeded by Eddie Gray, who comes from GlaxoSmithKline, where the doctor had served as president of Pharmaceuticals, Europe, since 2008.
- [By Keith Speights]
Of course, developing a product for a market with great opportunity doesn’t guarantee success for your investment strategy. An estimated 1 million people die each year from complications related to hepatitis B. Dynavax (NASDAQ: DVAX ) developed a hep-B vaccine, Heplisav, that showed tremendous promise. However, safety concerns derailed approval for the drug. While Heplisav might still reach the market, Dynavax’s experience highlights the risks even in a market with solid potential.
Top 5 High Tech Companies To Watch For 2014: Steelcase Inc.(SCS)
Steelcase Inc. designs, manufactures, and distributes furniture systems and seating products, user-centered technologies, and interior architectural products primarily in North America, Europe, and Asia. Its furniture systems portfolio consists of panel-based and freestanding furniture systems; and complementary products, such as storage, tables, and ergonomic worktools. The company also provides seating products, including ergonomic chairs; seating for collaborative or casual settings; and specialty seating for specific markets comprising healthcare and education. In addition, its interior architectural products include full and partial height walls and doors. Further, the company offers workplace strategy consulting, lease origination, and furniture and asset management services. Additionally, it designs, manufactures, and sells visual communication products, such as static and interactive electronic whiteboards to primary and secondary education markets, as well as manu factures and sells steel and ceramic surfaces to third-party fabricators for use in the manufacture of static whiteboards. It also designs and sells surface materials comprising textiles, wall coverings, shades, screens, and surface imagings primarily to architects and designers for use in business, residential, healthcare, and hospitality applications. It sells its products to corporate, government, healthcare, education, and retail customers through the Steelcase, Turnstone, Details, and Nurture brands; and Coalesse and Designtex brands. The company markets its products and services through a network of independent and company-owned dealers, as well as directly to end-use customers. The company was founded in 1912 and is headquartered in Grand Rapids, Michigan.
- [By Rick Aristotle Munarriz]
Bloomberg via Getty ImagesSteelcase, a leading maker of office furniture, reports this week; its earnings are a bellwether of how corporate America is faring. You can never know in advance all the news that will move the market in a given week, but some things you can see coming. From a pair of leading office furniture companies reporting on the same day to a popular used-car seller showing off its showroom, here are some of the things that will help shape the week that lies ahead on Wall Street. Monday — New Energy for the New Week: The new trading week kicks off with FuelCell Energy (FCEL) reporting. The builder of fuel cell power plants reports its latest quarterly results after the market closes on Monday. It’s been 10 years since FuelCell completed its first commercial fuel cell plant installation. Business is starting to pick up, as it has as many orders over the past two years combined as it did during the eight previous years combined. Revenue should continue to grow as FuelCell grows closer to profitability. Tuesday — Lone Wolf: Disney’s (DIS) “The Lone Ranger” was a flop earlier this year. It failed to break $90 million in domestic box office receipts, and the $260 million it amassed in gross ticket sales worldwide wasn’t enough to offset its massive production budget and cinematic distribution. Disney had fared well with Johnny Depp and director Gore Verbinski before. The two teamed up for the blockbuster success of Disney’s “The Pirates of the Caribbean” movie series. It convinced a jaded audience to return to the local multiplex for a movie about swashbucklers. But it couldn’t revive the Western genre this time around. Despite being a box office bomb, “The Lone Ranger” will get a chance at new life in the home market. It comes out on Blu-ray and DVD on Tuesday. Wednesday — Office Space: When it comes to stocks, it’s safe to say that Steelcase (SCS) and Herman Miller (MLHR) aren’t exactly the busy bees of the exchanges. On a typical day you w
- [By Shauna O’Brien]
Office furniture company Steelcase Inc. (SCS) announced on Thursday that it has named James Keane as its CEO.
Keane will take over the role of CEO in March 2014, replacing long term CEO James Hackett. Currently, Keane is the company’s president and Chief Operating Officer where he works with product development, manufacturing, marketing, sales and distribution.
Steelcase shares were mostly flat during Thursday morning trading. The stock is up 20% YTD.
Top 5 High Tech Companies To Watch For 2014: Uralkaliy OAO (URALL.PK)
Uralkaliy OAO (Uralkali OJSC) is a Russia-based company, which is engaged in the chemical industry. The Company specializes in the production of potash fertilizers. Its product portfolio comprises pink muriate of potash (PMOP), white muriate of potash (WMOP) and granular (GMOP). The Company is active through representative offices, located in Moscow and Beijing, as well as numerous subsidiaries, located countrywide and in Panama, Belarus, Singapore, Brazil and others. Uralkaliy OAO operates on the potassium and magnesium deposits located in Berezniki, Perm and Saint Petersburg. Its production assets include seven plants and five mines. Uralkaliy OAO sells its products domestically, as well as abroad in over 40 countries, including the United States, China, Brazil, India and South-East Asia, among others. Advisors’ Opinion:
- [By Tim Gallagher]
The potash spat continues to get uglier, as Belarus investigators reportedly intend to seize property and assets of Russia’s Uralkali (URALL.PK) following the collapse of the joint Russian-Belarussian potash venture.
- [By Chris Damas]
This morning Russian potash giant OJSC Uralkali (URALL.PK) presented first half 2013 financial and operating results and more importantly, much anticipated comments on the strategy of the company and the state of the international potash industry, the latter blind-sided by the leading potash company’s split with marketing partner JSC Belaruskali of Belarus.
Top 5 High Tech Companies To Watch For 2014: Celgene Corp (CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company’s primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquir ed Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufactur ing facility in Boudry, Switzerland.
Commercial! Stage Products
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatm ent of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.
THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THA LOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.
ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin’s T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to N ovartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.
Preclinical and Clinical-Stage Pipeline
The product candidates in the Company’s pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.
The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).
The Company’s oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company’s new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis a nd a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.
At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company’s research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn’s disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.
The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to de velop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.
The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).
- [By Mani]
Shares of Celgene Corporation (NASDAQ:CELG) are down 13 percent year-to-date, and sentiment has been relatively weak ahead of the FDA’s action date for Celgene’s Otezla (apremilast).
- [By Susan J. Aluise]
IBB’s top five holdings — which currently comprise about 36% of its total assets — are Biogen (BIIB), Gilead Sciences (GILD), Amgen (AMGN), Regeneron Pharmaceuticals (REGN) and Celgene (CELG). It’s also a fairly cheap way to invest in biotech stocks, with expenses just running 0.48% for exposure to IBB has gained 65% over the past year and its expense ratio is on par with the rest of the sector at 0.48.
- [By Ben Levisohn]
Today’s selloff started when three Democratic Party congressmen challenged Gilead Sciences (GILD) pricing of its hepatitis C-drug Sovaldi. The indiscriminate selling of biotech stocks–Biogen Idec (BIIB), Celgene (CELG) and Regeneron (REGN) all dropped at least 3.7%–suggests that investors have itchy trigger fingers, says Bernstein’s Geoffrey Porges and team:
Top 5 High Tech Companies To Watch For 2014: ConocoPhillips(COP)
ConocoPhillips operates as an integrated energy company worldwide. The company?s Exploration and Production (E&P) segment explores for, produces, transports, and markets crude oil, bitumen, natural gas, liquefied natural gas, and natural gas liquids. Its Midstream segment gathers, processes, and markets natural gas; and fractionates and markets natural gas liquids in the United States and Trinidad. The company?s Refining and Marketing (R&M) segment purchases, refines, markets, and transports crude oil and petroleum products, such as gasolines, distillates, and aviation fuels. Its Chemicals segment manufactures and markets petrochemicals and plastics. This segment offers olefins and polyolefins, including ethylene, propylene, and other olefin products; aromatics products, such as benzene, styrene, paraxylene, and cyclohexane, as well as polystyrene and styrene-butadiene copolymers; and various specialty chemical products comprising organosulfur chemicals, solvents, catalyst s, drilling chemicals, mining chemicals, and engineering plastics and compounds. The company?s Emerging Businesses segment develops new technologies and businesses. It focuses on power generation; and technologies related to conventional and nonconventional hydrocarbon recovery, refining, alternative energy, biofuels, and the environment. This segment also offers E-Gas, a gasification technology producing high-value synthetic gas. ConocoPhillips was founded in 1917 and is based in Houston, Texas.
- [By Lee Jackson]
ConocoPhillips (NYSE: COP) is a name that draws a solid rating at Baird. The company has spent the past five years divesting assets, and although it is cash rich, but the company has dampened earnings and growth expectations. Continued strong pricing could bode well for the company. Investors are paid a very nice 4.1% dividend. The Thomson/First Call price target for the stock is $75.83. Conoco closed Thursday at $67.90.
- [By Dividends4Life]
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description: 1. Avg. High Yield Price 2. 20-Year DCF Price 3. Avg. P/E Price 4. Graham Number CINF is trading at a discount to only 3.) above. The stock is trading at a 36.8% premium to its calculated fair value of $34.96. CINF did not earn any Stars in this section. Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description: 1. Free Cash Flow Payout 2. Debt To Total Capital 3. Key Metrics 4. Dividend Growth Rate 5. Years of Div. Growth 6. Rolling 4-yr Div. > 15% CINF earned two Stars in this section for 1.) and 2.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. The company has paid a cash dividend to shareholders every year since 1954 and has increased its dividend payments for 54 consecutive years. Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description: 1. NPV MMA Diff. 2. Years to > MMA The NPV MMA Diff. of the $62 is below the $500 target I look for in a stock that has increased dividends as long as CINF has. If CINF grows its dividend at 1.2% per year, it will take 5 years to equal a MMA yielding an estimated 20-year average rate of 3.68%. Memberships and Peers: CINF is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers™ Index and a Divid
- [By WWW.GURUFOCUS.COM]
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description: 1. Avg. High Yield Price 2. 20-Year DCF Price 3. Avg. P/E Price 4. Graham Number T is trading at a discount to only 3.) above. Since T’s tangible book value is not meaningful, a Graham number can not be calculated. The stock is trading at a 11.6% premium to its calculated fair value of $28.64. T did not earn any Stars in this section. Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description: 1. Free Cash Flow Payout 2. Debt To Total Capital 3. Key Metrics 4. Dividend Growth Rate 5. Years of Div. Growth 6. Rolling 4-yr Div. > 15% T earned one Star in this section for 3.) above and earned a Star for having an acceptable score in at least two of the four Key Metrics measured. The company has paid a cash dividend to shareholders every year since 1984 and has increased its dividend payments for 31 consecutive years. Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description: 1. NPV MMA Diff. 2. Years to > MMA T earned a Star in this section for its NPV MMA Diff. of the $1,161. This amount is in excess of the $500 target I look for in a stock that has increased dividends as long as T has. The stock’s current yield of 5.76% exceeds the 3.68% estimated 20-year average MMA rate. Memberships and Peers: T is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers™ Index and a Dividend Champion. The company’s peer group includes: CenturyLink, I
- [By Ben Levisohn]
ExxonMobil’s shares have dropped 11.1% so far this year, after reporting disappointing earnings and declining production. It’s also underperformed both ConocoPhillips (COP), which has fallen 8.5% this year, and Chevron (CVX),which is off 10.7%, though neither have exactly sparkled this year either.